Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: STARDUST trial
18 lug 2023 ·
9 min. 7 sec.
Iscriviti gratuitamente
Ascolta questo episodio e molti altri. Goditi i migliori podcast su Spreaker!
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was...
mostra di più
Dr. H. Tarik Kani talks to Dr. Axel Dignass (Germany) about his recent publication about the impact of Ustekinumab on health-related quality of life in moderate-to-severe Crohn’s disease which was an open-label, multicenter, randomized study evaluated the quality of life prospectively in Crohn’s patients who treated with Ustekinumab.
mostra meno
Informazioni
| Autore | UEG Journal |
| Sito | - |
| Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
